Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13885
UPID:
TBB2A_HUMAN
Alternative names:
Tubulin beta class IIa
Alternative UPACC:
Q13885; Q6FGZ8; Q8IWR2
Background:
Tubulin beta-2A chain, also known as Tubulin beta class IIa, plays a pivotal role in cell structure and function as the major constituent of microtubules. These cylindrical structures, composed of alpha- and beta-tubulin heterodimers, are essential for various cellular processes including cell division, intracellular transport, and maintenance of cell shape.
Therapeutic significance:
The Tubulin beta-2A chain's involvement in Cortical dysplasia, complex, with other brain malformations 5, highlights its potential as a target for therapeutic intervention. Understanding the role of Tubulin beta-2A chain could open doors to potential therapeutic strategies.